Keywords: roche, xeloda, fewer, side, effects, oral, capecitabine
Roche's Xeloda Has Fewer Side Effects
Article | 06 November 1998
Roche's oral Xeloda (capecitabine; 5-fluorouracil prodrug) produced anequivalent response to standard injectable chemotherapy but with a lower incidence of side ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
